Baidu
map

Hepatology:早期诊断肝癌的新型分子标记!

2017-10-24 MedSci MedSci原创

由于肝细胞癌(HCC)的早期检测可以显着提高存活率,因此,早期诊断HCC的精准方法在临床十分重要。近期,一项发表在杂志Hepatology上的研究旨在调查在癌前病变中可能检测到的HCC早期进展的分子标记。研究者们设计了基因选择策略,通过对人类不同分期HCC组织的转录组和临床病理资料的综合分析,包括癌前病变、低级别和高级别发育不良结节来鉴定潜在的驱动因子。通过检测HCC和癌前病变中所选择的分子来指导

由于肝细胞癌(HCC)的早期检测可以显着提高存活率,因此,早期诊断HCC的精准方法在临床十分重要。近期,一项发表在杂志Hepatology上的研究旨在调查在癌前病变中可能检测到的HCC早期进展的分子标记。研究者们设计了基因选择策略,通过对人类不同分期HCC组织的转录组和临床病理资料的综合分析,包括癌前病变、低级别和高级别发育不良结节来鉴定潜在的驱动因子。通过检测HCC和癌前病变中所选择的分子来指导基因选择过程。最终,研究者们选择了10个基因元件作为候选物,通过免疫组织化学染色显示,并与目前流行的三重HCC诊断标记:磷脂酰肌醇蛋白聚糖3,谷氨酰胺合成酶和热休克蛋白70相比,BANF1、PLOD3和SF3B4是HCC的决定标记,在HCC患者中,它们具有较好的早期诊断能力。此外,靶向灭活BANF1、PLOD3和SF3B4可以通过选择性调节EMT和细胞周期蛋白来抑制体外和体内肝肿瘤的发生。使用含有三种基因的siRNA的纳米颗粒的处理抑制了自发性小鼠HCC模型中的肝肿瘤发生率和肿瘤生长速度。此外研究还证明,SF3B4过表达触发SF3b复合物将肿瘤抑制因子KLF4转录物剪接到非功能性跳过的外显子转

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1382671, encodeId=e72213826e163, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426865, encodeId=2f93142686505, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255859, encodeId=71432558594b, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 25 13:49:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255714, encodeId=2717255e144a, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Oct 25 00:30:59 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1382671, encodeId=e72213826e163, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426865, encodeId=2f93142686505, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255859, encodeId=71432558594b, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 25 13:49:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255714, encodeId=2717255e144a, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Oct 25 00:30:59 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2017-10-26 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1382671, encodeId=e72213826e163, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426865, encodeId=2f93142686505, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255859, encodeId=71432558594b, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 25 13:49:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255714, encodeId=2717255e144a, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Oct 25 00:30:59 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2017-10-25 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1382671, encodeId=e72213826e163, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426865, encodeId=2f93142686505, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Oct 26 10:22:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255859, encodeId=71432558594b, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Oct 25 13:49:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255714, encodeId=2717255e144a, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Oct 25 00:30:59 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2017-10-25 明天会更好!

    谢谢分享谢谢分享

    0

相关资讯

JAMA Oncol:中国肝癌标化死亡率下降1/3

近日,《JAMA Oncol》杂志发表的2015年全球疾病负担研究(GBD)发现,1990-2015年间,东亚及西撒哈拉以南非洲地区则大幅下降,我国肝癌年龄标准化死亡率下降了1/3。(JAMA Oncol.10月5日在线版)

J Clin Gastroenterol:揭开法国肝硬化患者白蛋白的应用情况

2017年8月,发表在《J Clin Gastroenterol》的一项研究调查了法国肝硬化患者中白蛋白的应用情况。

Sci Trans Med:某些中草药成分可能增加肝癌风险

根据最近报告说,研究人员发现了广泛的证据表明中国传统中草药与亚洲肝癌的联系。

Front Pharmacol:研究揭示uc002mbe.2在TSA诱导的肝癌细胞死亡中的作用

研究已知长非编码RNA(lncRNA)涉及肝癌的发生。本课题组既往研究表明,lncRNA-uc002mbe.2的诱导与曲古抑菌素A(TSA)在肝细胞癌(HCC)细胞中的凋亡作用呈正相关。目前的研究进一步分析了uc002mbe.2在TSA诱导的肝癌细胞死亡中的作用。在HCC细胞的细胞质中,TSA诱导uc002mbe.2的水平显著升高。敲除uc002mbe.2可阻止TSA诱导的G2/M细胞周期停滞,p

AASLD2017: 又双叒叕刷存在感! “神药”阿司匹林可降低肝癌风险

如果要说全世界使用最广泛、知名度最高的药品,阿司匹林肯定是其中之一,且由于其用途广泛,更是赢得“世纪神药”的称谓。

Cell Chem Biol:研究发现一种糖类似物能有效切断癌细胞转移途径!

日本RIKEN全球研究组织的研究人员发现了一种防止癌症在肝脏中传播的方法。该研究发表在“细胞化学生物学”杂志上,详细介绍了如何用修饰岩藻糖处理可以破坏生物通路,从而阻止肝脏中的肝癌细胞侵袭健康的肝细胞。

Baidu
map
Baidu
map
Baidu
map